Outcome |
Relative effect (95% CI) |
Absolute effect (95% CI)1 |
Certainty of the Evidence (GRADE) |
Viral negative conversion D7 |
RR: 0.68 (0.38 - 1.21) |
35 fewer per 1000 (from 68 fewer to 23 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for no effect and the possibility for harm and low number of participants
|
1 trials
Gottlieb R, 2021
544 participants
|
|
Bamlanivimab (LY-CoV555) 75 per 1,000 (42 - 134) |
Placebo 110 per 1,000 |
|
Clinical improvement D28 |
RR: 1.11 (0.94 - 1.32) |
60 more per 1000 (from 33 fewer to 175 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for no effect and low number of participants
|
1 trials
Gottlieb R, 2021
478 participants
|
|
Bamlanivimab (LY-CoV555) 607 per 1,000 (514 - 721) |
Placebo 547 per 1,000 |
|
Clinical improvement D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above) D28 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above) D60 |
Outcome not yet measured or reported
|
|
All-cause mortality D28 |
RR: ( - ) |
Zero events in both groups
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious no events in both groups and low number of participants
|
3 trials
Chew K, 2021 (1); Chew K, 2021 (2); Gottlieb R, 2021
797 participants
|
|
Bamlanivimab (LY-CoV555) 0 per 1,000 ( - ) |
Placebo 0 per 1,000 |
|
All-cause mortality D60 |
RR: ( - ) |
Zero events in both groups
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious no events in both groups and low number of participants
|
2 trials
Chew K, 2021 (1); Chew K, 2021(2)
319 participants
|
|
Bamlanivimab (LY-CoV555) 0 per 1,000 ( - ) |
Placebo 0 per 1,000 |
|
Adverse events
|
RR: 1.21 (0.82 - 1.79) |
53 more per 1000 (from 45 fewer to 199 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Serious Inconsistency downgraded by 1 level: I²=:59.2% Indirectness: Not serious We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Serious due to very wide confidence interval consistent with the possibility for no effect and the possibility for harm and low number of participants. This outcome was not downgraded a further level, since it was alreaady downgraded for inconsistency, which also contributes to the imprecision.
|
3 trials
Chew K, 2021 (1); Chew K, 2021 (2); Gottlieb R, 2021
797 participants
|
|
Bamlanivimab (LY-CoV555) 305 per 1,000 (207 - 452) |
Placebo 252 per 1,000 |
|
Serious adverse events
|
RR: 0.73 (0.26 - 2.06) |
7 fewer per 1000 (from 18 fewer to 26 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants
|
3 trials
Chew K, 2021 (1); Chew K, 2021 (2); Gottlieb R, 2021
797 participants
|
|
Bamlanivimab (LY-CoV555) 18 per 1,000 (6 - 51) |
Placebo 25 per 1,000 |
|
Hospitalisation or death * |
RR: 0.76 (0.27 - 2.16) |
12 fewer per 1000 (from 37 fewer to 58 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants
|
2 trials
Checw K, 2021 (1); Chew K, 2021 (2)
319 participants
|
|
Bamlanivimab (LY-CoV555) 38 per 1,000 (14 - 108) |
Placebo 50 per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect